NEW YORK, NY
Plandaí Biotechnology (OTCQB: PLPL) has a strong executive team in place, a well thought out business plan, and now it's time for the company to make its products the star. These products include Plandaí's Phytofare botanical extracts such as its Green Tea Catechin Complex and the Limonoid Glycoside Complex, as well as a line of Diego Pellicer® medical cannabis products. It is the latter could make the company a leader in the marijuana industry.
Plandaí entered the marijuana space in November 2013, and since that time, the biotech has moved quickly to develop its Phytofare cannabis extracts, it has also found a branding partner in Diego Pellicer, Inc., and it named former Microsoft executive Jamen Shively as the company's Vice President of Global Marketing to build and market the brand of cannabis extracts.
None of this should be a surprise however, as Plandaí very well could be the most natural fit of any publicly traded company into the marijuana arena. After all, Plandaí is a producer of highly bioavailable plant extracts for the health, wellness, nutraceutical, and pharmaceutical industries, so adding an additional plant (cannabis) for development into the lineup of botanicals the company already works with (green tea, limonoids) only enhances its product offerings.
But, it doesn't stop there. What sets Plandaí apart from many other companies working with botanicals is its hydrodynamic extraction process that allows the company to use science to achieve the most bioavailability from those plants.
While tetrahydrocannabinol (THC) has demonstrated the ability to reduce tumors and slow the progression of Alzheimer's, it is the second largest constituent of cannabis, cannabidiol (CBD), which doesn't have psychoactive properties that will likely be the primary focus of Plandaí's testing. A number of recent studies that show the healing and treatment benefits of cannabinoids in diseases like diabetes, ALS, Crohn's disease, multiple sclerosis, among others favor a biotech company like Plandaí that will engage in its own studies using cannabis.
About Stock Market Media Group
SMMG is a full service IR firm specializing in Research and Content Development. It offers a platform for corporate stories to unfold through the media with Reports, Interviews and Articles. SMMG is compensated up to $650 by a third party for each article written. For more information and to read disclaimers and disclosures: www.stockmarketmediagroup.com/disclaimer.
Add to DiggBookmark with del.icio.usAdd to Newsvine
Stock Market Media Group
© 2019 Canjex Publishing Ltd. All rights reserved.